Genetic polymorphisms in vasoactive genes and preeclampsia: a meta-analysis

Eur J Obstet Gynecol Reprod Biol. 2007 Apr;131(2):115-26. doi: 10.1016/j.ejogrb.2006.10.005. Epub 2006 Nov 16.

Abstract

There are controversies in reports on the association of polymorphisms in endothelial nitric oxide synthase, angiotensinogen, angiotensin receptor type 1 and angiotensin-converting enzyme genes with an increased risk of developing preeclampsia. We performed a systematic search of published case-control studies through the PubMed database up to January 2006, and report the results of a meta-analysis of polymorphisms investigated in more than five studies: Glu298Asp in eNOS gene (9 analyses involving 1055 patients and 1788 controls), Met235Thr in AGT gene (13 analyses involving 1128 patients and 2278 controls), and intron 16 insertion-deletion polymorphism in ACE gene (10 analyses involving 1121 patients and 1361 controls). Statistically significant associations with preeclampsia were identified for the Met235Thr/AGT polymorphism: OR 1.65 (95% CI 1.19, 2.29) if the polymorphism is considered under the dominant genetic model, and OR 1.54 (95% CI 1.12, 2.11) under the recessive model. For insertion-deletion/ACE polymorphism, statistical significance was demonstrated when the polymorphism was considered under the recessive model: OR 1.51 (95% CI 1.17, 1.94). No single polymorphism was identified as having a major effect.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adult
  • Angiotensinogen / genetics*
  • Case-Control Studies
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Nitric Oxide Synthase Type III / genetics*
  • Peptidyl-Dipeptidase A / genetics*
  • Polymorphism, Genetic*
  • Pre-Eclampsia / etiology
  • Pre-Eclampsia / genetics*
  • Pregnancy
  • Receptor, Angiotensin, Type 1 / genetics*
  • Risk Factors

Substances

  • Receptor, Angiotensin, Type 1
  • Angiotensinogen
  • Nitric Oxide Synthase Type III
  • Peptidyl-Dipeptidase A